Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer Metastatic|BRCA 1 Gene Mutation|BRCA 2 Gene Mutation
Interventions: DRUG: Olaparib|DRUG: Physician's choice chemotherapy
Sponsor: AstraZeneca
Collaborators: Myriad Genetic Laboratories, Inc.|Merck Sharp & Dohme LLC